MicroPort NeuroTech™ Completes Clinical Implantation of NUMEN™ in the UK

Wales, United Kingdom, 26 May 2023 - Recently, MicroPort NeuroTech™ (Shanghai) Co., Ltd., (hereinafter referred to as “MicroPort NeuroTech™"), has successfully completed the first two implantation surgeries of NUMEN™ Detachable Embolization Coils (hereinafter referred to as "NUMEN™ Coils") in the United Kingdom.

Both of the initial clinical implantation surgeries were performed by Dr. Sastry's team at the University Hospital of Wales. The first patient, a 41-year-old male, was diagnosed with a ruptured saccular aneurysm in the left internal carotid artery. The treatment involved a balloon-assisted coil embolization technique, and five NUMEN™ Coils were implanted, which successfully achieved occlusion of the aneurysm. The second patient was diagnosed with a ruptured aneurysm measuring 12mm x 8.6mm in size in the A1 segment of the left anterior cerebral artery. The surgical team implanted five NUMEN™ Coils, achieving good immediate occlusion. The surgeon and the team expressed their full affirmation of the excellent framing stability, clear visualization, and dense packing of the NUMEN™ Coils during the procedures.

NUMEN™ Coils are characterized by their stable formation and dense packing. The ultra-fine platinum tungsten wire and unique three-dimensional structure achieve a balance between flexibility and support, reducing the force against the aneurysm wall and enhancing the safety of coil embolization. The product includes three series with 177 sizes, allowing doctors to choose the appropriate coil size for precise filling based on different cases, which provides more embolization treatment options for intracranial aneurysm surgery.

So far, MicroPort NeuroTech™ products have been successfully introduced into more than ten overseas countries and regions. The successful completion of the first clinical implantations of NUMEN™ Coils in the United Kingdom will further accelerate the product's entry into the European market. In the future, MicroPort NeuroTech™ will continue to devote itself to introducing innovative and high-quality products into more regions, benefiting global patients with cerebrovascular diseases.